The impact of serum testosterone level as prognosis factor for CRPC with enzalutamide or Abraterone

The impact of serum testosterone level as prognosis factor for CRPC with enzalutamide or Abraterone - PC-TES

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019493

Enrollment

Registered

2015-10-26

Start date

2015-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration resistant prostate cancer :CRPC

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: The candidate for administration with enzalutamide or Abraterone in CRPC

Exclusion criteria

Exclusion criteria: without informed consent to entry in this study

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Countries

Japan

Contacts

Public ContactNirihito Soga

Aichi cancer center hospital Urology

n-soga@aichi-cc.jp052-762-6111

Outcome results